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New treatment modalities are urgently needed to better manage advanced breast
cancer. Combination therapies are usually more effective than monotherapy. In this
context, the use of cyclic and acyclic O,N-acetals derivative compounds in combination
with the suicide gef gene shown a potent anti-tumor activity and represent a new
generation of anticancer agents. Here, we evaluate the use of the gef gene to promote
and increase the anti-tumor effect of cyclic and acyclic O,N-acetals purine derivatives
and elucidate their mechanisms of action. Among all compounds tested, those with
a nitro group and a cyclic pattern structures (FC-30b2, FC-29c, and bozepinib) are
the most benefited from the gef gene effect. These compounds, in combination with
gef gene, were able to abolish tumor cell proliferation with a minimal dose leading to
more effective and less toxic chemotherapy. The effect of this combined therapy is
triggered by apoptosis induction which can be found deregulated in the later stage
of breast cancer. Moreover, the combined therapy leads to an increase of cell post-
apoptotic secondary necrosis that is able to promote the immunogenicity of cancer
cells leading to a successful treatment. This data suggests that this novel combination
therapy represents a promising candidate for breast cancer treatment.
Keywords: gef gene, 1,4-benzoxazepin-2,6-dichloropurine, breast cancer, combined therapy, gene therapy
INTRODUCTION
In accordance with the World Health Organization criteria, breast cancer is the malignancy
with the highest incidence among women, with 30% of estimated new cases. Despite recent
improvements in diagnosis and treatment, both incidence and prevalence are increasing, especially
in industrialized countries. Thus, this malignancy is known to be the most important cause of
cancer mortality among women, representing 14% of estimated all cancer deaths (Siegel et al.,
2017). Conventional treatments (chemotherapy, radiotherapy, surgery, and hormone therapy) are
efficient in early stages of the disease, however, they are only palliative for advanced breast cancer
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and have many side effects. Moreover, patients treated with
current systemic therapies are known to suffer from multiple side
effects (Malecki, 2012). These data uncover the demand to reduce
the dose used in both chemotherapeutics and radiation treatment
protocols below the most effective doses, or the withdrawal of a
first-line treatment.
Our previous studies highlighted the relevance of the
antiproliferative activity of cyclic and acyclic O,N-acetals in
either human breast and colon cancer cell lines in the
micromolar range (Díaz-Gavilán et al., 2007; Conejo-García
et al., 2008; Nuñez et al., 2008; López-Cara et al., 2011). Among
them, (R,S)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-
tetrahydro-4,1-benzoxazepine-3-yl]-9H-purine (ACG-812b also
called bozepinib, Figure 1) has shown to be the most potent
and selective anti-tumor compound being able to leads apoptosis
induction in breast and colon cancer cells mediated by the
double-stranded RNA-dependent protein kinase (López-Cara
et al., 2011; Marchal et al., 2013). Moreover, bozepinib inhibits
the formation of both mamo- and colono-spheres and is able
to abrogate the aldehyde dehydrogenase enriched (ALDH+)
cancer stem cells (CSCs) subpopulations in the low micromolar
range. CSCs represent a small tumor subpopulation known to
be responsible for promoting and maintaining tumor growth
by enhancing their self-renewal and differentiation capacity.
They also play a key role in chemo and radiotherapy resistance
due to their high metastatic potential and the ability to enter
in a quiescent state (Visvader and Lindeman, 2008). The
in vivo activity of Bozepinib was also shown trough the tumor
and metastasis inhibition assessed in xenotransplanted nude
mice without presenting sub-acute toxicity (Ramírez et al.,
2014).
In addition, novel anti-tumor strategies like suicide gene
therapy are attractive due to the failure of current treatment
approaches and the chemoresistance to cure a high percentage of
patients with advanced breast cancers. The mechanism in witch
suicide gene therapy is based involves the delivery of a cytotoxic
protein encoded by a gene into tumor cells (Amer, 2014). There
are several suicide gene systems with proven anti-tumor efficacy
(Navarro et al., 2016). With the goal to improve this therapy,
our group has developed a novel and effective therapy strategy
based on the use of gef gene. This gene belongs to a family
with cell-killing functions in E. coli. The protein encoded by gef
gene, a protein of 50 amino acids is anchored to the cytoplasmic
membrane by the N-terminal portion and is able to induce
cellular respiration arrest and cell death (Poulsen et al., 2005).
In human tumor cells, gef gene has a potent anti-tumor effect
by induction of cell cycle arrest and apoptosis (Boulaiz et al.,
2003a,b) which could be used as a promising complementary
strategy for the common treatment choices.
It is known that combination therapies are usually more
effective than monotherapy. They can be used to achieve several
important objectives that are less probable using monotherapy.
Firstly, it provides an increase in cell death within an acceptable
toxicity range for each drug, whenever that the dosage is not
compromised and the tumor is sensitive to each medication;
secondly, taking into account that the tumor is formed by a
heterogeneous population, it increases the probability that some
cells will respond in comparison with a single agent and finally,
FIGURE 1 | Chemical structure of the compounds.
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the use of a combined therapy may delay the apparition of
drug resistance by triggering a rapid cell death and reducing
the tumor mass (Dear et al., 2013). Currently, the combination
of several systemic agents such as taxanes, aromatase inhibitors,
monoclonal antibodies and capecitabine are used as a first-line
treatment for metastatic breast cancer and, thus, appear to be
associated with improved survival (Chia et al., 2007; Cardoso,
2016; Mansour et al., 2017). The successful use of these agents
as first-and/or second-line treatments in clinical trials is reflected
in current guideline recommendations to treat advanced breast
cancer (Cardoso et al., 2017). However, in most cases, the
combination of the classic chemotherapies leads to more side
effects. Hence, the need to develop new therapeutic strategies
capable of inhibiting, at very low doses, the proliferation of
both quiescent and rapidly proliferating tumor cells to avoid
recurrence and metastasis and improve the patient’s quality of
life is imperative. With this goal and based on our experience
using toxin gene-based therapy and the new synthesized cyclic
and acyclic O,N-acetals, we developed a new strategy based on
the combination of these therapeutic tools. The main goal of this
work was to evaluate whether gef gene is able to enhance the
anti-tumor effect of bozepinib and its derivatives ACG-812c, FC-
26c, FC-29b, FC-29d, and FC-30b (Figure 1) and to explore the
mechanisms involved in the effectiveness of this combination.
MATERIALS AND METHODS
Cell Lines
The breast cancer cell line MCF-7 was kindly provided by Dr. N.
Olea of the Sánchez Mora Tumoural Biology Institute (University
Hospital of Granada). The MCF-7TG cell line, a gef -expressing
breast cancer cell line controlled by a mouse mammary tumor
virus promoter and inducible by dexamethasone (Dex) was
derivates from MCF-7 cells following methodology previously
described by us (Boulaiz et al., 2003b). A selected MCF-
7pMAMneo empty vector positive clone was also used. Non-
tumoral breast cell line MCF-10A (ATCC: CRL-10317) was
provided by the Cell Bank of the University of Granada
(Granada, Spain). MCF-7 cells were cultured in a humidified
atmosphere at 37◦C with 5% CO2 and Dulbecco’s modified Eagle
Medium (DMEM) (Gibco, Grand Island, NY, United States) with
10% heat-inactivated fetal bovine serum (FBS) (Gibco), 2.7%
sodium bicarbonate, 2% L-glutamine, 1% Hepes buffer, 500 mg/L
ampicillin and 40 mg/L gentamicin. MCF-7TG cells were grown
in the same medium described above supplemented by 200 µg/ml
geneticin G418 and 1µM Dex to induce gef gene expression.
MCF-10A grown in DMEM/F12 medium with 5% horse serum
(HS), 0.02 µg/ml epithelial growth factor (EGF), 0.5 µg/ml
hydrocortisone, 100 ng/ml cholera toxin and 0.01 µg/ml insulin.
Drugs and Treatments
The cyclic and acyclic O,N-acetals purine derivatives were
synthesized as previously described (López-Cara et al.,
2011). The only acyclic structure is ACG-812cF1. The
target compounds present the 2,6-dicholoropurine moiety
linked by position 9 with the only exception of FC-30b2
where the purine is linked by position 7. The structures
are substituted with p-nitrobenzenesulfonyl (bozepinib
and ACG-812cF1), o-nitrobenzenesulfonyl (FC-26c, FC-
30b2), p-hydroxylaminebenzenesulfonyl (FC-29d) and
p-aminobenzenesulfonyl (FC-29b) groups (Figure 1).
DMSO was used to dissolve the compounds and after
that they were aliquoted and stored at −20◦C. Prior the
experiment, each aliquot was diluted in medium to obtain
the desired concentrations. The final DMSO concentration
(used as a solvent) in cell culture was ≤0.1% v/v of DMSO.
This concentration has no effect on cell proliferation. In each
experiment we also use cells in medium with DMSO as controls.
In Vitro Cytotoxicity Assays
To assess the effect of the different drugs on cell viability we used
the sulforhodamine-B colorimetric assay. Cells were resuspended
and seeded at a density of 5 × 103 cells/well onto 12-well plates
kept growing for 24 h. After that, the compounds were added
at different concentrations to the cells (0.5, 0.7, 1, 2, 5, and
10 µM) (Figure 1). After 72 h treatment, the medium was
discarded and fresh medium and treatment was added. Cells were
maintained for 3 days more with the treatment. Finally, they
were processed as previously described (Boulaiz et al., 2003b)
using a Titertek Multiscan apparatus (Flow Laboratories, Irvine,
United Kingdom) at 492 nm. We used the cell number for each
cell stock before each cell growth experiment to set the linearity
of the sulforhodamine-B assay. To calculate the IC50 values we
used semilogarithmic dose–response curves to make a linear
interpolation. All of the experiments were performed in triplicate
wells for each treatment and were repeated at least twice.
In Vitro Cell Proliferation Assays
MCF-7, MCF-7TG, and MCF-7pMAMneo cells were seeded at
a density of 25 × 103/well into six-well plates using the culture
conditions above mentioned. After 24 h, fresh medium was added
to the cells and treated with IC50 and 2∗IC50 of drugs cited
in Table 1. No treatment was added to the control groups. To
ensure the expression of the gef gene, MCF-7TG cells medium
was always treated with 1 µM Dex. Cells in culture were always
treated with or without drugs every 3 days when medium was
changed up to the end of the assay. Four plates were used
TABLE 1 | Antiproliferative activitiesa for cyclic and acyclic O,N-acetals
compounds against the MCF-7 and MCF7TG cancer cell lines, and the epithelial
MCF-10A cell line.
Compound MCF-7 IC50 (µM) MCF-7TG IC50 (µM) MCF-10A IC50 (µM)
Bozepinib 1.232 ± 0.05 0.56 ± 0.01 6.33 ± 0.03
FC-26c 2.6 ± 0.10 0.65 ± 0.03 9.187 ± 0.08
ACG-812c-F1 9.43 ± 0.07 8.75 ± 0.18 17.48 ± 0.12
FC-29b 5.021 ± 0.12 1.9 ± 0.02 4.04 ± 0.09
FC-29d 8.98 ± 0.3 6.7 ± 0.01 47.12 ± 0.05
FC-30b2 7.75 ± 0.06 1.8 ± 0.08 9.9 ± 0.08
aAll experiments were conducted in duplicate and gave similar results. The data
are means ± SEM of three independent determinations. The treatment time was 6
days.
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to run each treatment and time point (0, 3, 6, 9, 12, and 15
days of treatment). After the end of the treatment, we used
sulforhodamine-B to stain the cells as previously described.
Flow Cytometric Analysis of the Cell
Cycle
Cells were grown at 70% confluence and treated with either
DMSO alone or with different concentrations of the compounds
corresponding to their IC50 values. Flow cytometry analysis
was carried out after 72 h of treatment as described (Marchal
et al., 2004). The results were representative of three independent
experiments.
Analysis of Apoptosis by Propidium
Iodide and Annexin V-FITC Staining
Apoptosis was detected using the apoptosis detection kit for
annexin V-FITC (Pharmingen, San Diego, CA, United States) by
flow cytometry according to Boulaiz et al. (2003a). Both reagents
annexin V-FITC and IP non-vital dye allowed the differentiation
among: viable cells (no staining for both dyes), cells undergoing
early apoptosis (positive for annexin V-FITC and negative for
PI), cells undergoing late apoptosis (positive for both dyes),
and necrotic cells (only showed IP staining). The results were
representative of three independent experiments.
Use of Confocal Microscopy for
Apoptosis Detection
Labtek chamber-slide 8-well plates were used to seed the cells at a
confluence of 5× 103 cells/well. After 24 h to allow cell adhesion,
the treatment was added using the concentration needed for each
compound. After aspirate culture medium, cells were washed
using cold phosphate buffered saline (1X). Then we proceeded to
incubation with both annexin V-FITC and propidium iodide (PI)
for 15 min at room temperature in the dark. After that, cells were
washed with binding buffer, preserved using mounting medium
and cover slips before confocal microscopic imaging. Finally, cells
were imaged by confocal microscopy using a Leica SP2 Confocal
Microscope.
Statistical Analysis
Data collected represent the mean ± standard deviation. Two-
tailed Student t-test was used to compare differences between two
groups. A two-tailed p-values < 0.05 was considered statistically
significant.
RESULTS
gef Gene Expression Enhances
Cytotoxicity of Cyclic and Acyclic
O,N-Acetals Compounds
We have previously described the inhibition of cell proliferation
due to gef gene activity in different cancer cell lines (Boulaiz
et al., 2003a,b, 2008, 2014). In this work, we used a breast
cancer cell line derived from the MCF-7 that stably expresses the
gef gene after induction with 1 µM of dexamethasone. Firstly,
we confirmed the expression of gef gene in MCF-7TG cells by
RT-PCR (Figure 2A) and determine its anti-tumor effect by
measuring the proliferation rate of MCF-7TG induced with 1 µM
of dexamethasone during 15 days and comparing it with the
MCF-7 parental cell, MCF-7 induced with 1 µM Dex (MCF-
7Dex), MCF-7 transfected with gef without Dex induction (MCF-
7T) and MCF-7 transfected with pMAMneo empty vector (MCF-
7pMAMneo) used as controls (Figure 2B). Our results showed
that MCF-7Dex, MCF-7pMAM-neo and MCF-7T showed a
similar proliferation rate than MCF-7 cell line demonstrating
that Dex and transfection process don’t have any antiproliferative
effect on this cell line. However, in MCF-7TG we observed that gef
gene induces an inhibition of the proliferation of 59.36 ± 2.9%
compared to MCF-7.
Moreover, we have reported the potent anti-tumor effect of the
novel cyclic and acyclicO,N-acetals purine derivatives: bozepinib,
FC-26c, ACG-812c-F1, FC-29b, FC-29d, and FC-30b2 in a variety
of cancer cell lines (López-Cara et al., 2011). In our study, we
determined their inhibitory concentration (IC50) after 6 days of
treatment in both MCF-7 and MCF-7TG cell lines. As shown in
Table 1, the IC50 values for the different drugs were markedly
reduced in the MCF-7TG cell line. This means that the gef gene
expression sensitizes the cells to the different compounds; hence
a much lower amount of the drugs is needed to induce the death
of the same number of cells. Thus, the compounds that improved
their antiproliferative effect in presence of the gef gene were FC-
30b2, FC-26c, FC-29b, and bozepinib with 76.77%, 75%, 62.15%,
and 54.55%, respectively (Figure 2C). These values confirm
the potent anti-tumor effects resulting from the gef gene/drugs
combination.
FC-29d and ACG-812c-F1 were benefited to a lesser extent
from the gef gene expression with a decrease of the IC50 of 24.63%
and 7.211%, respectively.
Moreover, a comparison between the two tumor cell lines
(MCF-7 and MCF-7TG) and the MCF-10A epithelial-like cell
line was established in order to define the selective activity
of the compounds through the determination of the in vitro
therapeutic index (TI) (Table 2). TI was better by far for almost
all compounds in MCF-7TG than MCF-7 (Table 2). In addition,
in MCF-7TG cells, the best TI was achieved by FC-26c, bozepinib,
FC-29d, FC-30b2, and FC-29b (TIs = 14.13, 11.30, 7.032, and 5.5,
2.12, respectively). The ACG-812c-F1 did not show differences
regarding TI with or without the gef gene expression (Table 2).
To test the antiproliferative action of the different compounds
against MCF-7 and MCF-7TG cells over time, we measured the
proliferation rate of these cell lines after being exposed to IC50
and double IC50 of the compounds (Table 1) during 3, 6, 9,
12, and 15 days of treatment (Figure 3A). Our results showed
that until day 6 both MCF-7 and MCF-7TG cell lines shares a
similar pattern growth, with a minimum proliferation rate in
those exposed to IC50 and 2∗IC50 of different compounds. From
day 6, differences between the cell line expressing the gef gene and
the control cell line begin to be noticed, whether they are treated
with the IC50 or with the double IC50 of the different drugs.
Thus, after 15 days of treatment by bozepinib in MCF-7
76% and 89.42% of growth inhibition using IC50 (1.23 µM)
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FIGURE 2 | (A) Detection of the gef gene expression in MCF-7TG cells by RT-PCR. (B) Determination of the effects of gef gene expression on MCF-7 cell
proliferation. MCF-7 Dex, MCF-7pMAM-neo, MCF-7TG were used as control. (C) Comparison between antiproliferative activities of bozepinib, FC-26c, FC-29b, and
FC-30b2 against the MCF-7 and MCF-7TG cancer cell lines, and the MCF-10A epithelial cell line. Data are expressed as the mean ± standard error of the mean of
three independent experiments. ∗P < 0.05, ∗∗P < 0.01 (t-test).
and 2∗IC50 (2.46 µM), respectively, was observed, while in the
MCF-7TG cell line an inhibition of 81.42% and 97.14% using
IC50 (0.56 µM) and 2∗IC50 (1.12 µM), respectively, has been
achieved. The same trend was observed for FC-26c. After 15
days of treatment in MCF-7 an inhibition of 61.6% and 82,34%
using IC50 (2.6 µM) and 2∗IC50 (3.2 µM), respectively, was
reached, while in the MCF-7TG cell line we have achieved an
inhibition of 82,34% and 97.43% using IC50 (0.65 µM) and
2∗IC50 (1.3 µM), respectively. In the same way, the FC-30b2
showed an inhibition of 82% and 96% using IC50 (7.75 µM) and
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TABLE 2 | Therapeutic indexes for cyclic and acyclic O,N-acetals compounds.








2∗IC50 (15.5), respectively, in MCF-7 cells, while in the MCF-
7TG cell line we have achieved a growth inhibition of 81.14% and
97.57% using IC50 (1.8 µM) and 2∗IC50 (2.6 µM), respectively
(Figure 3B). However, the FC-29b was the only compound that
failed to induce a total inhibition of proliferation using 2∗IC50.
In fact, without the gef gene expression, this compound showed
an inhibition of 61.91% and 70.48% using IC50 (5.02 µM) and
2∗IC50 (10.04 µM), respectively. Similar percentages have been
obtained using IC50 (1.9 µM) and 2∗IC50 (3.8 µM) in the
presence of gef gene (60% and 70.48%, respectively) (Figure 3B).
These results indicate that the compounds have a synergistic
effect with the gef gene but in a different way. When combined
with gef gene the exposure to bozepinib, FC-26c and FC-30b2
has an enhanced synergetic effect while FC-29b has an additive
synergetic effect.
Apoptosis Is Involved in the Synergistic
Effect of Combined Therapy
Finally, in order to determine the role of apoptosis in the
observed growth inhibition, we proceeded to use both flow
cytometry and confocal microscopy. To carry out these assays,
cells were treated with the IC50 values of the different compounds
and stained using PI and annexin V after 72 h of drug treatment.
MCF-7 and MCF-7TG non-treated cells were used as control
(Figure 4A). In our MCF-7 control culture, 79.14 ± 3.95% of
the cells were viable, 8.15 ± 0.40% were in early apoptosis, and
3.6± 0.18% undergoes late or final stages of apoptosis (P < 0.05).
Interestingly, MCF-7 cell line treated for 72 h with the novel
compounds suffered a significant increase in the subpopulation
presenting early apoptosis in comparison to the control cells,
showing percentages varying from 40.41± 2.02%, 37.63± 1.88%,
57.62± 2.88%, and 73.27± 3.66% for bozepinib, FC-26c, FC-29b,
and FC-30b2, respectively. The late apoptotic cell subpopulation
percentage was also increased in MCF-7 cell line treated with the
drugs when compared to control cells (Figure 4B).
Moreover, in MCF-7TG cell line 52.89 ± 2.41% of the cells
were viable, 27.14± 1.35% were in early apoptosis, 19.24± 1.15%
were in the late stages of apoptosis and 0.74 ± 0.05% were
necrotic. However, the combined expression of gef gene and
different drugs induced a marked increase on necrotic cells
(Figure 4B) varying from 47.03 ± 1.07%, 54.38 ± 2.3%,
51.92 ± 2.09%, 65.09 ± 2.47% for bozepinib, FC-26c, FC-29b,
and FC-30b2 for each compound. Notably, the levels of necrotic
cells induced by the combined therapy significantly increased in
comparison with the corresponding drugs or gef gene alone.
Confocal microscopy using FITC-conjugated annexin V and
the nuclear non-vital dye PI was used to study the effects of
compounds on the pattern of cell death. Early apoptosis, late
apoptosis or cell death and necrosis can be observed; viable
cells are not visible. In MCF-7 treated cells we observed signs
of late apoptosis after the treatment revealed by the extrusion
of sunspot-like apoptotic bodies (Figures 5A,B,D). We can
also observe early apoptotic cells (Figures 5C,E,F). MCF-7TG
cells treated with different drugs showed some early and late
apoptotic cells (Figures 5G,H,J,K) but much more necrotic cells
(Figures 5H,I,L).
Combined gef Gene Expression and
Drug Treatment Involves a G0/G1
Accumulation in MCF-7TG Cells
To study whether the antiproliferative effect of the combined
treatment with compounds and gef gene involves changes in cell-
cycle distribution, MCF-7 and MCF-7TG cell lines were treated
using the IC50 of bozepinib, FC-26c, FC-29b, and FC-30b2 for
72 h and then analyzed by flow cytometry (Figure 6A). MCF-7
cell culture contained 65.03 ± 3.21% G0/G1 cells, 17.41 ± 0.81%
S-phase cells and 17.56 ± 0.87% G2/M-phase cells. Interestingly,
after gef gene induction for 72 h, MCF-7TG cell line suffered a
gradual disappearance of G2/M (7.6 ± 0.28%) phase cells and
they accumulate on S-phase (27.47 ± 1.34%). A similar behavior
was observed after treatment of MCF-7 cell line with FC-26c
while the other three drugs bozepinib, FC-29b and FC-30b2,
caused an increase in the G2/M phase in the MCF-7 cell line
(22.98± 1.14%, 26.12± 1.20%, and 33.22± 1.66%, respectively)
and a decrease in S phase (12.29 ± 0.90%, 9.47 ± 0.30%,
0.63± 0.01%, respectively).
Nevertheless, the combined expression of gef gene and drugs
induced a marked cell cycle arrest in G0/G1 phase being
85.98± 4.29%, 81.25± 4.05%, 80.07± 4.01%, and 72.96± 3.50%
for bozepinib, FC-26c, FC-29b, and FC-30b2, respectively, and at
the expense of cells in the S-phase and G2/M-phase population
(Figure 6B).
DISCUSSION
Conventional cancer treatment strategies have been aimed at
eradicating all cancer cells. Over the past 25 years, the systemic
chemotherapy treatment of advanced breast cancer has suffered
an evolution from the “anthracycline era” in the beginning of the
1980s, crossing the stage of the “taxane era” of the 1990s and
finally establish in the “biological era” of the 2000s (Nabholtz
et al., 2002). Standard chemotherapeutic approaches have relied
on the maximum tolerated dose of cytotoxic drugs with a
long off-therapy interval, leading to poor response, toxicity and
eventual multidrug resistance (Kwak et al., 2017). In addition, the
advances reached in the cancer development area have allowed
researchers to identify two different populations inside tumors, a
differentiated tumor cell subpopulation and an undifferentiated
cell subpopulation or progenitor cells, also named CSCs. This
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FIGURE 3 | Determination of the effects of the combination of gef gene expression with bozepinib, FC-26c, FC-29b, and FC-30b2 on cell proliferation. (A) MCF-7
and MCF-7TG cell lines were treated with IC50 and 2∗ IC50 of different compounds during 15 days. Data are expressed as the mean ± standard error of the mean of
three independent experiments. (B) Percentage of cell viability after 15 days of treatment with different compounds expressed in comparison to the maximal MCF-7
(100%). The statistical analysis was performed using each cell line without drug exposure as controls. ∗P < 0.05, ∗∗P < 0.01 (t-test).
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FIGURE 4 | Cell death is enhanced by combination of gef gene and drugs. MCF-7 and MCF-7TG cell lines were mock-treated (control) or treated with IC50 of the
most antiproliferative compounds for 72 h. Treated cells were then trypsinized and analyzed by flow cytometry using an annexin V-fluorescein isothiocyanate
detection kit. (A) Representative images from flow cytometry analysis. (B) Data are expressed as the mean ± standard error of the mean of three independent
experiments. ∗∗P < 0.01 (t-test).
heterogeneity of the tumor is responsible for the failure of most
chemotherapeutic agents that eliminate only the cells that are in
full division leaving quiescent cells such as the CSCs alive which
in the long term results in recurrence and metastasis8. Thus,
new treatment modalities combinations are urgently needed
to better manage advanced breast cancer, including recurrent
and metastatic cases (Lee and Djamgoz, 2017). In this context,
we have previously described that on the one hand, different
cyclic and acyclic O,N-acetals derivatives compounds and on
the other hand, the suicide gef gene, shown potent anti-tumor
activity and represent a new generation of anticancer agents
(Boulaiz et al., 2003a,b, 2008, 2014; Nuñez et al., 2008; López-
Cara et al., 2011; Ramírez et al., 2014). In this study, we
have demonstrated that the combination of both therapeutic
tools trigger the apparition of an adjuvant effect that enhances
its anti-tumor activity in different breast cancer cell lines.
Additionally, the gef gene sensitizes the breast cancer cells to
the different compounds thus allowing decreasing its IC50 and
increasing its TI.
It has been demonstrated that combination therapy enhances
the efficacy of the therapy making possible to overcome the
shortcomings of chemotherapy (Lee et al., 2010; Liu et al., 2011).
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FIGURE 5 | Confocal analysis of MCF-7 (A) and MCF-7TG (G) cells
mock-treated and treated with bozepinib (B,C,H,I), FC-26c (D,J), FC-29b
(E,K), and FC-30b2 (F,L). Cells were stained with annexin V-FITC and PI as
described in the section “Materials and Methods.” Early apoptosis (stained
positive for annexin V-FITC and negative for PI), late apoptosis or cell death
(stained positive for both annexin V-FITC and PI) and necrosis (stained positive
for PI) can be observed; viable cells are not visible. In MCF-7 treated cells we
observe cells characteristic of late (A,B,D) and early apoptosis (C,E,F).
MCF-7TG cells treated with different drugs showed some early and late
apoptotic cells (G,H,J–L) but much more necrotic cells (H,I,K,L).
The advances in the use of novel therapies combining cytotoxic
drugs and gene therapy has been recently reported in different
cancer types (Deharvengt et al., 2007; Abaza et al., 2008; Fandy
et al., 2008; Lu et al., 2009; Touati et al., 2014; Zhang et al., 2015).
In addition, several studies reported the ability of gef gene to
improve the therapeutical effects of paclitaxel and doxorubicin
in lung and breast cancer cells, respectively (Prados et al., 2008,
2010). In this work, we have selected bozepinib, FC-26c, ACG-
812c-F1, FC-29b, FC-29d, and FC-30b2 as the six most potent
and less toxic cyclic and acyclic O-N-acetals purine derivatives
that we have previously synthesized in our group to analyze
whether gef gene improves their therapeutic activity in breast
cancer cells. Our results showed that combined therapy induces
a decrease on IC50 values of all compounds in different degree.
Thus, FC-30b2, FC-26c, FC-29b, and bozepinib mostly improved
their antiproliferative effect in a remarkable way in the presence
of gef gene with enhanced chemosensitivity up to 4.31-fold,
4-fold, 2.65-fold, and 2.2-fold, respectively. However, FC-29d
and ACG-812c-F1 compounds have benefited to a lesser extent
from the gef gene expression with only 1.08-fold and 1.34-
fold enhanced chemosensitivity, respectively. Similar results were
obtained by combination of gef with paclitaxel and docetaxel
in MCF-7 breast cancer (Prados et al., 2010). The reason why
ACG-812c-F1 and FC-29d were benefit lesser from the expression
of the gef gene than the other compounds could be due to
their chemical structures. These compounds present either an
acyclic structure or the nitro group reduced to the hydroxylamino
one, respectively. This seems to be detrimental to the benefit of
combination therapy.
Moreover, gef gene greatly improved the TI of the different
compounds. The ratio of the toxic dose to the therapeutic dose
(In vitro TI = IC50 non-tumor cell line/IC50 tumor cell line) is
defined as the in vitro TI of a drug (Kao et al., 2009). The best TI
was achieved by FC-26c, bozepinib, FC-29d, FC-30b2, and FC-
29b (TIs = 14.13, 11.30, 7.032, 5.5, and 2.12, respectively). The
ACG-812c-F1 did not show significant differences regarding TI
with or without the gef gene expression.
After the determination of the anti-tumor activity of the
compounds against the different breast cell lines, we selected
those that showed a balanced great cytotoxic effect and a better
TI in the presence of gef gene, in order to determine its anti-
tumor effect over time and its mechanism of action. Our results
demonstrated that the expression of the gef gene combined
with lower doses of the compounds caused a greater inhibition
of cell proliferation compared to the control treated with high
dose of drug only. Thus, until day 6 the same proliferation
rate was observed with or without gef gene expression using
IC50 and 2∗IC50 for each selected compound. From day 6, we
observed that the compounds have a synergistic effect with the
gef gene but in a different way. Combined with gef gene the
exposure to bozepinib, FC-26c and FC-30b2, had an enhanced
synergetic effect resulting in a total inhibition of proliferation
using 2∗IC50 (1.12 µM, 1.3 µM, and 2.6 µM, respectively).
While FC-29b, had an additive synergistic effect, it was only
succeeded in inhibiting proliferation by 70% using 2∗IC50 in
the presence (3.8 µM) or absence (10.04 µM) of gef gene.
The biological data described here, support that the presence
of the nitro group and the cyclic structures are the essential
structural parameters for the synergistic effect with the gef gene
of the tested compounds. We can find a similar case in the
literature about an improvement of the cytotoxic activity related
to the fusion gene CDglyTK. This gene encodes an enzyme
with bifunctional activity in which are involved both CD- and
TK-specific activities increasing the effectiveness, broad-spectral,
and safe when compared to the use of the gene alone (Guowei
et al., 2006). Moreover, in previous works we had shown that
combination of gef with doxorubicin also decreased the viability
of the MCF-7 cell line when compared to treatment alone.
However, the effective doses (10 µM) were much higher than
those necessary to induce a similar effect to that obtained by
the FC-30b2, FC-29c, and bozepinib compounds (Prados et al.,
2010). In addition, cell viability was reduced by 65.13% when gef
and apoptin were synergistically co-expressed in colon DLD-1
treated cells after 10 days of treatment with doxycycline, while
only the expression of gef or apoptin gene alone obtained a
reduction of 35.9% and 47.95%, respectively (Boulaiz et al., 2014).
The fact that the potentiation of the effect of combined therapy
on cell proliferation is uncovered after a 6 days treatment was
observed also after gef and apoptin genes co-expression and
may be due of the needing for a target amount of gef protein
in the tumor cells to trigger cell death (Boulaiz et al., 2014).
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FIGURE 6 | Combination of gef gene expression and drugs induce cell cycle arrest in G0/G1. MCF-7 and MCF-7TG cells were mock-treated (control) or treated with
IC50 of bozepinib, FC-26c, FC-29b, and FC-30b2 for 72 h. Then, cells were trypsinized and analyzed by FACScan to distinguish populations of cells in different
phases of the cycle as described in the section “Materials and Methods.” (A) Representative images from flow cytometry analysis. (B) Data are expressed as the
mean ± standard error of the mean of three independent experiments. ∗P < 0.05, ∗∗P < 0.01 (t-test).
The requirement of a critical concentration of gef protein to
trigger cell death was reported in prokaryotic cells (Ronchel
et al., 1998). These values confirm the potent anti-tumor effects
resulting from combination of gef gene with very low doses
of bozepinib, FC-26c, and FC-30b2 which has resulted in a
total inhibition of proliferation after 15 days of treatment.
Differences in the synergetic effect between FC-29b and the
other compounds suggest the involvement of different signaling
pathways as reported with other anti-tumor enantiomers
(De Fátima et al., 2008).
It is known that cyclic and acyclic O,N-acetals purine
derivatives can trigger apoptosis in tumor cells including breast
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and colon carcinoma (López-Cara et al., 2011; Marchal et al.,
2013). Our group previously reported apoptosis induction due
to the gef gene effect in breast (Boulaiz et al., 2003b, 2011)
and colon (Ortiz et al., 2012) cancers. To clarify whether the
combined effect of gef and bozepinib, FC-26c, FC-29b, and FC-
30b2 compounds induces cytotoxicity by apoptosis and/or other
mechanisms, cells with or without gef gene expression were
treated with IC50 of different compounds and were stained with
annexin V and PI. After that we performed both flow cytometry
and confocal microscopy studies. These studies demonstrated
that cytotoxicity due to the combined therapy was triggered
by the induction of both apoptosis and cell death induced
by a post-apoptotic secondary necrotic process. To assess the
apoptosis induction we used the MCF-7 human breast cancer
cell line. This cell line revealed to be very resistant where the
demonstration of programmed cell death by known apoptosis-
inducing agents has proven difficult and only few cytotoxic agents
act preferentially through an apoptotic mechanism (Chadderton
et al., 2000). In fact, at 72 h post-drug treatment with the
novel compounds, MCF-7 cells were involved in an increase
of early and late apoptotic cell subpopulations compared to
the untreated control. However, the combined expression of
gef gene and different drugs induced a marked increase on
necrotic cells. This phenomenon was also observed after the co-
expression of the gef and apoptin genes in colon cancer cells
(Boulaiz et al., 2014). This necrosis should be classified as post-
apoptotic secondary necrosis what is the natural outcome of
the complete apoptotic program as described by Silva (2010).
In fact, when the apoptotic cells are excessive in vitro and also
when the phagocytic capacity of the organism is overwhelmed,
the apoptotic cells progress to a secondary necrosis stage
loosing progressively their structural integrity and they suffer
of ballooning, permeabilization of the plasma membrane and
finally they release cytoplasm contents (Sachet et al., 2017).
However, it has been reported recently that the regulation of
the secondary necrosis, rather than accidental (Rogers et al.,
2017), constitutes a valuable target for the use of compounds with
novel pharmacological activities aimed at enhance the immune
response against cancer cell death (Galluzzi and Kroemer, 2017).
The effects of the combined therapy to trigger cell death were
also assessed by confocal microscopy after the use of FITC-
conjugated annexin V and the nuclear non-vital PI stains.
In the MCF-7 cell line treated with different compounds we
observe cells characteristic of late apoptosis after the treatment.
They can be seen in the form of sunspots the extrusion of
apoptotic bodies (fragments of chromatin and cellular organelles,
membrane coated). MCF-7TG cells treated with different drugs
showed some early and late apoptotic cells but much more
necrotic/secondary necrotic cells. In the cells used as controls,
most of them showed negative staining for both dyes, except
for a low number of cells showing the staining features of
apoptosis. Our results supports the effect of the compounds
over some stages of the apoptotic process where are described
a series of morphological and biochemical types of cell death
(Gooch and Yee, 1999; Marchal et al., 2004). Furthermore, our
previous studies show that when used separately, both gef gene
and bozepinib, one of the cyclic compounds that we analyzed
in this study, are able to induce apoptosis through different
pathways. It has been reported the association between the
expression of the gef gene in the MCF-7 breast cancer cell
line with an improvement in the prognosis and induction of
apoptosis mediated by p53 signaling pathway (Boulaiz et al.,
2011). However, our studies showed that bozepinib treatment
had no effect on p53 and its induction was not necessary to
trigger the apoptotic process in the breast and colon cancer
cell lines under study (Ramírez et al., 2014). This could explain
the enhanced synergetic effect obtained by combining both
therapeutic tools.
The cell cycle is characterized by cell division and self renew.
This process is subdivided in interphase (G1, S, and G2 phases)
and mitosis, where the cell replicates the DNA and suffer a
nuclear division (McIntosh, 2016; Maes et al., 2017). In the cell
cycle progression from a phase to the next one are involved cell
cycle proteins which regulates and coordinates the activity several
checkpoint pathways. The abnormal activity of these cell cycle
proteins and checkpoint pathways results in deregulation of cell
cycle progression that is known to be one of the key hallmarks of
cancer. Analysis of the cell cycle in MCF-7 showed that gef gene
alone can induce the disappearance of cells undergoing G2/M
phase leading to the accumulation of cells in the of S-phase.
A similar behavior has been observed after treatment of MCF-7
cell line with FC-26c while the other three drugs bozepinib, FC-
29b, and FC-30b2, caused an increase in the G2/M phase and a
decrease in S phase. Nevertheless, the combined expression of
gef gene and drugs induced a marked cell-cycle arrest in G0/G1
phase at the expense of cells in the S-phase and G2/M phase
population. These results are consistent with the literature since
many anticancer agents exerts its activity by arresting the cell
cycle at the G0/G1, S and G2/M phase and finally they induce
apoptosis (Murray, 2004; Kwan et al., 2016).
CONCLUSION
In summary, to our knowledge, this is the first demonstration
that gef gene mediated therapy synergizes with cyclic and
acyclic O,N-acetals purine derivatives and enhance cell death
in breast cancer cells. Within all the compounds that we have
tested FC-30b2, FC-29c, and bozepinib are those that have most
benefited from the gene gef expression being able to reach
a total inhibition of tumor cell proliferation with a minimal
dose, enhancing the effectiveness and decreasing the toxicity
associated to chemotherapy. Thus, we have assessed how the
presence of the nitro group and also the cyclic pattern of
these structures affect to the synergistic effect with the gef
gene.
This combined therapy is characterized by the induction
of the apoptotic process which may be deficient in advanced
or metastatic breast cancer. Moreover, the combined therapy
increased cell post-apoptotic secondary necrosis, a promising
target for the development of novel 1,4-benzoxazepin-2,6-
dichloropurine drugs that may enhance the immunogenicity
of cancer cells leading to successful new treatments. However,
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further studies are necessary to establish the mechanism of action
of this combined therapy and its usefulness in vivo.
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